Navigation Links
DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
Date:9/24/2008

ATLANTA, Sept. 24 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has again recommended that the two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) continue under the current protocol, without change. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing clinical studies.

These clinical trials, known collectively as the FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), consist of two double masked, randomized, multi-center trials that are following 956 patients in the U.S., Canada, Europe and India for 36 months in support of a planned global registration filing, with safety and efficacy assessed after 24 months of follow-up. Enrollment for the FAME study was completed in October 2007.

"Alimera is excited about the potential of Iluvien to help the growing number of people suffering from DME," said Alimera CEO Dan Myers. "The DSMB's recommendation to continue the FAME Study without change keeps the development for Iluvien on track for regulatory submissions in early 2010."

Iluvien is an intravitreal insert being developed for the treatment of DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

Currently, nearly 24 million people, or 8 percent of the population, in the U.S. have diabetes. Over time, all diabetics are at risk of developing some form of diabetic retinopathy, an ophthalmic condition of diabetes. In the U.S., diabetic retinopathy causes approximately 12,000 to 24,000 new cases of blindness each year, making diabetes the leading cause of new cases of blindness in adults aged 20 to 74. Based on published data, Alimera estimates that there are as many as 300,000 new cases of DME each year and 1 million people have DME. There are no ophthalmic drug therapies currently approved by the U.S. Food and Drug Administration for the treatments of DME.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has acquired options to exclusive, worldwide licenses for two classes of nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, which Alimera is studying as potential treatments for conditions such as the dry form of age-related macular degeneration (AMD), particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.


'/>"/>
SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
9. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 7D Surgical announced today that ... U.S. Food and Drug Administration (FDA) and a ... North American commercial launch of its innovative Machine-vision ... the 7D Surgical System.  The ... and machine vision algorithms to eliminate the long-standing ...
(Date:1/23/2017)... and Markets has announced the addition of the "Needle Free Drug ... report to their offering. ... Highlights: The report provides a detailed analysis ... Market forecasts till 2025, using estimated market values as the ... Regions and Countries Key developments and strategies observed in ...
(Date:1/23/2017)... Alberta , January 23, 2017 ... del riñón (r enal) y ... sola dosis de a pabetalone    ... hoy los resultados preliminares de un ensayo en fase ... con discapacidad de riñón (renal) severa. Los datos demostraron ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... of Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor ... holds a bachelor degree in religious education and a master degree in theology. , ...
(Date:1/24/2017)... ... 23, 2017 , ... OSF Ventures, the corporate investment arm ... platform headquartered in Silicon Valley that connects startups to corporations and invests in ... three-year agreement to be a corporate sponsor of Plug and Play’s program for ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s ... all people and by all people shines as a bright beacon of determination ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... translation and localization services for life science companies, has achieved ISO 17100:2015 ... TÜV SÜD America. ISO 17100 is the globally recognized standard that establishes ...
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters ... management and evaluation leaders with decades of experience who remain current practitioners in ... States healthcare system, there is a renewed demand for versatile, data-driven leadership.The American ...
Breaking Medicine News(10 mins):